A population pharmacokinetic-pharmacodynamic model for simvastatin that predicts low-density lipoprotein-cholesterol reduction in patients with primary hyperlipidaemia

Basic and Clinical Pharmacology and Toxicology

Volumn 109, Issue 3, 2011, Pages 156-163

  Kim, Jimyon ^a,b   Ahn, Byung Jin ^c   Chae, Hong Seok ^a,b   Han, Seunghoon ^a,b   Doh, Kichan ^a,b   Choi, Jeongeun ^d   Jun, Yong K ^d   Lee, Yong W ^d   Yim, Dong Seok ^a,b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

^c Dongguk University   (South Korea)

^d Boryung Pharm Co Ltd   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SIMVASTATIN;

ADULT; ARTICLE; DOSE RESPONSE; HUMAN; HUMAN EXPERIMENT; HYPERLIPIDEMIA; MALE; NORMAL HUMAN; PHARMACODYNAMICS; POPULATION MODEL; PREDICTION; PRIORITY JOURNAL;

ADULT; ASPIRIN; CHOLESTEROL, LDL; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; SIMVASTATIN; YOUNG ADULT;

EID: 80051582025     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2011.00700.x     Document Type: Article

References (33)

1. Mauro VF. Clinical pharmacokinetics and practical applications of simvastatin. Clin Pharmacokinet 1993;24:195-202.
2. 4S Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
3. Crouse J III, Byington R, Furberg C. HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data. Atherosclerosis 1998;138:11-24.
4. Law M, Wald N, Rudnicka A. Quantifying effect of statins on LDL cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ 2003;326:1423-7.
5. Lennerns H, Fager G. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet 1997;32:403-25.
6. Prueksaritanont T, Vega J, Zhao J, Gagliano K, Kuznetsova O, Musser B et al. Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects. J Clin Pharmacol 2001;41:573.
7. Neuvonen P, Niemi M, Backman J. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81.
8. Vickers S, Duncan CA, Chen IW, Rosegay A, Duggan DE. Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug. Drug Metab Dispos 1990;18:138-45.
9. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
10. Grundy S. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med 1988;319:24.
11. Zhao J, Xie I, Yang A, Roadcap B, Rogers J. Quantitation of simvastatin and its β-hydroxy acid in human plasma by liquid-liquid cartridge extraction and liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2000;35:1133-43.
12. Prueksaritanont T, Qiu Y, Mu L, Michel K, Brunner J, Richards K et al. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil. Pharm Res 2005;22:1101-9.
13. Vickers S. In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase. Drug Metab Dispos 1990;18:476.
14. Jusko W, Ko H. Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 1994;56:406-19.
15. Merck. ZOCOR (simvastatin) Tablets package insert. Available at: (last accessed on 10 April 2011).
16. Jeong M. Clinical effects of simvastatin in patients with hypercholesterolemia. Korean Circ J 1997;27:415-23.
17. Kim W, Kim K, Kim S, Kang H, Choue C, Song J et al. The effect of cholesterol lowering therapy on endothelium-dependent vasodilation in hypercholesterolemia. J Korean Soc Echocardiogr 1999;7:56-62.
18. Chung S, Bae K, Park S. The change of cholesterol level and IL-6, CRP in unstable angina patients with hypercholesterolemia after low dose simvastatin therapy. Korean Circ J 2002;32:981-8.
19. Kim M, Park Y, Park J, Shin D, Kim Y, Kim G. Evaluation of short-term hypolipidemic effect and safety of simvastatin (Zocor (R)) in patients with hyperlipidemia. Yeungnam Univ J Med 2003;20:152-9.
20. Son J, Koh K, You S, Ryu W, Ahn J, Kim H et al. Effects of simvastatin alone or combined with ramipril on nitric oxide bioactivity and inflammation markers in hypercholesterolemic patients. Korean Circ J 2003;33:1053-9.
21. Lee K, Cho W, Jeong M, Lim Y, Park K, Cha J. Statin reduced the platelet CD63 and CD40L expression in atherosclerotic ischemic stroke with hyperlipidemia. J Korean Neurol Assoc 2004;22:453-8.
22. Prueksaritanont T, Gorham L, Ma B, Liu L, Yu X, Zhao J et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997;25:1191.
23. Bottorff M, Hansten P. Long-term safety of hepatic hydroxymethyl glutaryl coenzyme A reductase inhibitors: the role of metabolism - monograph for physicians. Arch Intern Med 2000;160:2273.
24. Kajinami K. Statin response and pharmacokinetics variants. Expert Opin Pharmacother 2005;6:1291.
25. Tang B, Kalow W. Variable activation of lovastatin by hydrolytic enzymes in human plasma and liver. Eur J Clin Pharmacol 1995;47:449-51.
26. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105.
27. Faltaos DW. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients. Fundam Clin Pharmacol 2006;20:321.
28. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H et al. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005;78:330-41.
29. Tan C, Loh L, Tai E. Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience. Singapore Med J 2003;44:635-8.
30. Sacks FM. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001.
31. Shepherd J. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301.
32. Chung N. STATT: a titrate-to-goal study of simvastatin in Asian patients with coronary heart disease. Clin Ther 2001;23:858.
33. Wu C, Sy R, Tanphaichitr V, Hin A, Suyono S, Lee Y. Comparing the efficacy and safety of atorvastatin and simvastatin in Asians with elevated low-density lipoprotein-cholesterol - a multinational, multicenter, double-blind study. J Formos Med Assoc 2002;101:478.